Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Ophthalmologic manifestations of systemic lupus erythematosus: the effect of autoimmune inflammation
https://doi.org/10.33667/2078-5631-2024-29-50-55
Abstract
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of unknown etiology with heterogeneous clinical manifestations. One third of patients with SLE have various ophthalmologic symptoms. Eye lesions may be the initial signs of SLE and lead to severe complications, including vision loss. Ophthalmologic manifestations are often associated with the degree of activity of systemic inflammation. Dry keratoconjunctivitis, or secondary Sjogren's syndrome, is the most common ophthalmologic manifestation of SLE. Episcleritis and scleritis are less common, but they can be the first signs of SLE. Unilateral or more often bilateral retinopathy associated with retinal vasculitis can cause visual loss of varying severity. A number of adverse ophthalmologic events occur on the background of long-term use of drugs used currently for the treatment of SLE: posterior subcapsular cataract and secondary open-angle glaucoma when using glucocorticosteroids, retinopathies – in cases of long-term use of hydroxychloroquine. The side effects of other immunosuppressive and biological agents are still poorly understood. Regular ophthalmologic examinations are recommended for all patients with SLE.
About the Authors
S. S. Spitsina
A. B. Zborovsky Research Institute of Clinical and Experimental Rheumatology; Volgograd State Medical University
Russian Federation
Russian Federation
Svetlana S. Spitsina, junior research, Assistant
Clinical biochemistry Laboratory; Hospital therapy department
Volgograd
L. N. Shilova
Volgograd State Medical University
Russian Federation
Russian Federation
Ludmila N. Shilova, DM Sci (habil.), assistant professor, head of Dept
Hospital Therapy Dept
Volgograd
E. E. Mozgovaya
A. B. Zborovsky Research Institute of Clinical and Experimental Rheumatology
Russian Federation
Russian Federation
Elena E. Mozgovaya, PhD Med, leading researcher
Clinical Biochemistry Laboratory
Volgograd
S. A. Bedina
A. B. Zborovsky Research Institute of Clinical and Experimental Rheumatology; Volgograd State Medical University
Russian Federation
Russian Federation
Svetlana A. Bedina, PhD Med, senior researcher, assistant professor
Clinical biochemistry Laboratory; Clinical laboratory Diagnostics Dept
Volgograd
A. S. Trofimenko
A. B. Zborovsky Research Institute of Clinical and Experimental Rheumatology
Russian Federation
Russian Federation
Andrei S. Trofimenko, PhD Med, head of Laboratory
Clinical Biochemistry Laboratory
Volgograd
References
1. Hysa E, Cutolo CA, Gotelli E, Paolino S, Cimmino MA, Pacini G, Pizzorni C, Sulli A, Smith V, Cutolo M. Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system. Autoimmun Rev. 2021 May; 20 (5): 102796. DOI: 10.1016/j.autrev.2021.102796
2. Luboń W, Luboń M, Kotyla P, Mrukwa-Kominek E. Understanding Ocular Findings and Manifestations of Systemic Lupus Erythematosus: Update Review of the Literature. Int J. Mol Sci. 2022 Oct 14; 23 (20): 12264. DOI: 10.3390/ijms232012264
3. Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. British Journal of Ophthalmology. 2016; 100: 135–141.
4. McMenamin PG. The distribution of immune cells in the uveal tract of the normal eye. Eye (Lond) 1997; 11 (Pt 2): 183–93.
5. Keino H, Horie S, Sugita S. Immune privilege and eye-derived T-regulatory cells. J. Immunol Res. 2018 May 20; 2018: 1679197. doi: 10.1155/2018/1679197
6. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014; 384: 1878–1888.
7. Talat L, Lightman S, Tomkins-Netzer O. Ischemic retinal vasculitis and its management. J. Ophthalmol. 2014; 2014: 197675.
8. Yen YC, Weng SF, Chen HA, Lin YS. Risk of retinal vein occlusion in patients with systemic lupus erythematosis: a population-based cohort study. Br. J. Ophthalmol. 2013; 97: 1192–1196.
9. Sandhu V, Quan M. SLE and serum complement: causative, concomitant or coincidental? Open Rheumatol J. 2018 Sep 18; 12: 171. doi: 10.2174/1874312901812010171
10. D’Cruz DP, Houssiau FA, Ramirez G, Baguley E, McCutcheon J, Vianna J. et al. Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol. 1991 Aug; 85 (2): 254–61. doi: 10.1111/j.1365–2249.1991.tb05714.x
11. Renaudineau Y, Dugu´e C, Dueymes M, Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002 Dec; 1 (6): 365–72. doi: 10.1016/s1568-9972(02)00063-0.12848993
12. Atehortúa L, Rojas M, V´ asquez GM, Castano ˜ D. Endothelial alterations in systemic lupus erythematosus and rheumatoid arthritis: potential effect of monocyte interaction. Mediat Inflamm. 2017; 2017: 9680729. doi: 10.1155/2017/9680729
13. Erkan D, Salmon JE. The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk. J. Haematol. 2016 Mar 5; 33 (1): 1–7. doi: 10.4274/tjh.2015.0197
14. Niewold TB, Clark DN, Salloum R, Poole BD. Interferon alpha in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010; 2010: 948364. doi: 10.1155/2010/948364
15. Jones Buie JN, Oates JC. Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms. Am. J. Med. Sci. 2014 Aug; 348 (2): 168–75. doi: 10.1097/MAJ.0000000000000284
16. Knight JS, Kaplan MJ. Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis. Curr. Opin. Rheumatol. 2012 Sep; 24 (5): 441–50. doi: 10.1097/BOR.0b013e3283546703.22617827
17. Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U S A. 2010 May 25; 107 (21): 9813–8. doi: 10.1073/pnas.0909927107
18. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011 Sep 27; 7 (12): 691–9. doi: 10.1038/nrrheum.2011.132
19. Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin Immunopathol. 2013 Jul; 35 (4): 455–63. DOI: 10.1007/s00281-013-0375-7
20. Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 2011 Jul 1; 187 (1): 538–52. doi: 10.4049/jimmunol.1100450
21. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE – Mechanisms and management. Nat. Rev. Rheumatol. 2012 Feb 14; 8 (4): 214–23. doi: 10.1038/nrrheum.2012.14
22. Chang PC, Chen WS, Lin HY, Lee HM, Chen SJ. Combined central retinal artery and vein occlusion in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2010 Feb; 19 (2): 206–9. doi: 10.1177/0961203309345751
23. Wu C, Dai R, Dong F, Wang Q. Purtscher-like retinopathy in systemic lupus erythematosus. Am. J. Ophthalmol. 2014 Dec; 158 (6): 1335–41. doi: 10.1016/j.ajo.2014.09.001
24. Munguia-Realpozo P, Mendoza-Pinto C, Sierra Benito C, Escarcega RO, GarciaCarrasco M, Mendez Martinez S, et al. Systemic lupus erythematosus and hypertension. Autoimmun. Rev. 2019 Oct; 18 (10): 102371. doi: 10.1016/j.autrev.2019.102371
25. Kono S, Takashima H, Suzuki D, Terada T, Konishi T, Miyajima H. Orbital myositis associated with discoid lupus erythematosus. Lupus. 2014 Feb; 23 (2): 220–2. DOI: 10.1177/0961203313517156
26. Stavrou P, Murray PI, Batta K, Gordon C. Acute ocular ischaemia and orbital inflammation associated with systemic lupus erythematosus. Br. J. Ophthalmol. 2002 Apr; 86 (4): 474–5. DOI: 10.1136/bjo.86.4.474
27. Mseddi M, Marrekchi S, Meziou TJ, Sellami D, Kammoun B, Feki J, Zahaf A, Turki H. Lupus érythémateux discoïde et paupière. Une série de 9 patients [Discoid lupus erythematosus with eyelid involvement. A series of nine patients]. J. Fr. Ophtalmol. 2007 Mar; 30 (3): 247–9. French. DOI: 10.1016/s01815512(07)89585-4
28. Lo Y, Jee SH, Cheng YP. Periorbital heliotrope edema as an uncommon manifestation of juvenile-onset systemic lupus erythematosus. Kaohsiung J. Med. Sci. 2020 Sep; 36 (9): 759–760. DOI: 10.1002/kjm2.12254
29. Mullaaziz D., Maden S., Deren O., Özkayalar H. Periorbital lupus erythematosus profundus: A case report and review of the literature. Turkderm. 2020; 54: 114–116.
30. Darjani A, Rafiei R, Mesbah A, Golmohammadi R, Rafiee B, Movaseghi M. Discoid Lupus Erythematosus Presenting as Upper Eyelid Edema and Erythema. Acta Med. Iran. 2017 Jul; 55 (7): 474–476.
31. Theisen E, Tiao J, Fedeles F. Periorbital discoid lupus erythematosus: A retrospective study. JAAD Case Rep. 2022 Jun 2; 25: 78–82. DOI: 10.1016/j.jdcr.2022.05.024
32. Kemeny-Beke A, Szodoray P. Ocular manifestations of rheumatic diseases. Int Ophthalmol. 2020 Feb; 40 (2): 503–510. DOI: 10.1007/s10792-019-01183-9
33. Wang L, Xie Y, Deng Y. Prevalence of dry eye in patients with systemic lupus erythematosus: a meta-analysis. BMJ Open. 2021 Sep 29; 11 (9): e047081. DOI: 10.1136/bmjopen-2020–047081
34. Schonberg S, Stokkermans TJ. Episcleritis. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
35. Dutta Majumder P, Agrawal R, McCluskey P, Biswas J. Current Approach for the Diagnosis and Management of Noninfective Scleritis. Asia Pac J. Ophthalmol (Phila). 2020 Dec 7; 10 (2): 212–223. DOI: 10.1097/APO.0000000000000341
36. Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 1999 Mar-Apr; 43 (5): 379–96. DOI: 10.1016/s0039-6257(98)00051-4
37. Cao Y, Zhang W, Wu J, Zhang H, Zhou H. Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. J Ophthalmol. 2017; 2017: 7298026. DOI: 10.1155/2017/7298026. Epub 2017 Jul 13.
38. Lally L, Sammaritano LR. Vasculitis in antiphospholipid syndrome. Rheum Dis Clin. North. Am. 2015; 41 (1): 109–23, ix. DOI: 10.1016/j.rdc.2014.09.009
39. Montehermoso A, Cervera R, Font J, Ramos-Casals M, García-carrasco M, Formiga F, Callejas JL, Jorfán M, Griñó MC, Ingelmo M. Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Semin Arthritis Rheum. 1999 Apr; 28 (5): 326–32. DOI: 10.1016/s0049–0172(99)80017-1
40. Liu R, Wang Y, Xia Q, Xu T, Han T, Cai S, Luo SL, Wu R, Shao Y. Retinal thickness and microvascular alterations in the diagnosis of systemic lupus erythematosus: a new approach. Quant Imaging Med. Surg. 2022 Jan; 12 (1): 823–837. DOI: 10.21037/qims-21–359
41. Radosavljević A, Karadžić J, Kovačević I, Ljikar J, Devečerski G. Severe vaso-occlusive retinopathy associated with systemic lupus erythematosus. Vojnosanit Pregl. 2016 Dec; 73 (12): 1164–7. DOI: 10.2298/VSP150605136R
42. Leone P, Prete M, Malerba E, Bray A, Susca N, Ingravallo G, Racanelli V. Lupus Vasculitis : An Overview. Biomedicines. 2021 Nov 5; 9 (11): 1626. DOI: 10.3390/biomedicines9111626
43. Dias-Santos A, Tavares Ferreira J, Pinheiro S, Cunha JP, Alves M, Papoila AL, Moraes-Fontes MF, Proença R. Choroidal thickness changes in systemic lupus erythematosus patients. Clin Ophthalmol. 2019 Aug 20; 13: 1567–1578. DOI: 10.2147/OPTH.S219347
44. Arevalo JF, Lowder CY, Muci-Mendoza R. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2002 Dec; 13 (6): 404–10. DOI: 10.1097/00055735-200212000-00011
45. Zink JM, Singh-Parikshak R, Johnson CS, Zacks DN. Hypopyon uveitis associated with systemic lupus erythematosus and antiphospholipid antibody syndrome. Graefes Arch Clin Exp Ophthalmol. 2005 Apr; 243 (4): 386–8. DOI: 10.1007/s00417-004-1022-8
46. Man BL, Mok CC, Fu YP. Neuro-ophthalmologic manifestations of systemic lupus erythematosus : a systematic review. Int J. Rheum Dis. 2014 Jun; 17 (5): 494–501. DOI: 10.1111/1756-185X.12337
47. de Andrade FA, Guimarães Moreira Balbi G, Bortoloti de Azevedo LG, Provenzano Sá G, Vieira de Moraes Junior H, Mendes Klumb E, Abramino Levy R. Neuro-ophthalmologic manifestations in systemic lupus erythematosus. Lupus. 2017 Apr; 26 (5): 522–528. DOI: 10.1177/0961203316683265
48. Jimenez-Vega A, Herencia-Anaya K, Palacios-Sánchez C, Cáceres-Del-Carpio J. Choroidopathy and optic neuropathy in systemic lupus erythematosus, a case report. Arch Soc Esp Oftalmol (Engl Ed). 2022 Jan; 97 (1): 34–39. DOI: 10.1016/j.oftale.2021.12.001
49. Nakamagoe K, Yanagiha H, Miyake Z, Kondo Y, Hiyama T, Ishii A, Kaji Y, Oshika T, Sumida T, Tamaoka A. Monocular Oculomotor Nerve Disorder Manifesting as Cranial Neuropathy in Systemic Lupus Erythematosus. Intern Med. 2018 Dec 1; 57 (23): 3445–3449. DOI: 10.2169/internalmedicine.1106-18
50. Conigliaro P, Cesareo M, Chimenti MS, Triggianese P, Canofari C, Barbato C, Giannini C, Salandri AG, Nucci C, Perricone R. Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. Autoimmun Rev. 2019 Mar; 18 (3): 247–254. DOI: 10.1016/j.autrev.2018.09.011
51. Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017 Jun; 31 (6): 828–845. DOI: 10.1038/eye.2016.298
52. Apostolopoulos D, Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017 Apr 1; 56 (suppl_1): i114–i122. DOI: 10.1093/rheumatology/kew406
Review
For citations:
Spitsina S.S., Shilova L.N., Mozgovaya E.E., Bedina S.A., Trofimenko A.S. Ophthalmologic manifestations of systemic lupus erythematosus: the effect of autoimmune inflammation. Medical alphabet. 2024;(29):50-55. (In Russ.) https://doi.org/10.33667/2078-5631-2024-29-50-55
Views:
176
Email this article 